Totally agree with you Dan, there is no good news to be had from this Adcom announcement. Going by history the FDA will do whatever is most negative when it comes to Amarin. Look at the track record with NCE, ANCHOR, 1A issues, etc...
Anyone who thinks we're going to get some approval before the Adcom is employing some very aggressive wishful thinking.
Fortunately JT knows this now, and the company is in a much stronger position than it was in Oct 2013.
Market Data 
Markets 
AI
